A detailed history of Rafferty Asset Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 26,651 shares of NUVB stock, worth $77,021. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,651
Previous 16,171 64.81%
Holding current value
$77,021
Previous $47,000 29.79%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.3 - $3.83 $24,103 - $40,138
10,480 Added 64.81%
26,651 $61,000
Q2 2024

Aug 13, 2024

BUY
$2.58 - $3.69 $41,721 - $59,670
16,171 New
16,171 $47,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $495 - $6,900
1,708 Added 13.0%
14,847 $33,000
Q2 2022

Aug 12, 2022

BUY
$3.24 - $5.85 $42,570 - $76,863
13,139 New
13,139 $43,000
Q4 2021

Feb 10, 2022

SELL
$7.75 - $10.05 $77,662 - $100,711
-10,021 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$7.78 - $10.0 $77,963 - $100,210
10,021 New
10,021 $100,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $628M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.